Literature DB >> 9576954

CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.

W K Wang1, T Dudek, Y J Zhao, H G Brumblay, M Essex, T H Lee.   

Abstract

The seven-transmembrane CCR5 was recently found to double as a coreceptor for a genetically diverse family of human and nonhuman primate lentiviruses. Paradoxically, the main region of the envelope protein believed to be involved in CCR5 utilization was mapped to hypervariable region 3, or V3, of the envelope glycoprotein gp120. In this study, we addressed the question of whether functional convergence in CCR5 utilization is mediated by certain V3 residues that are highly conserved among HIV type 1 (HIV-1), HIV type 2, and simian immunodeficiency virus. Site-directed mutagenesis carried out on three such V3 residues revealed that the Arg-298 of HIV-1 gp120 has an important role in CCR5 utilization. In contrast, no effect was observed for the other residues we tested. The inability of Arg-298 mutants to use CCR5 was not attributed to global alteration of gp120 conformation. Neither the expression, processing, and incorporation of mutant envelope proteins into virions, nor CD4 binding were significantly affected by the mutations. This interpretation is further supported by the finding that alanine substitutions of five residues immediately adjacent to the arginine residue had no effect on CCR5 utilization. Taken together, our data strongly suggests that the highly conserved Arg-298 residue identified in the V3 of HIV-1 has a significant role in CCR5 utilization, and may represent an unusually conserved target for future anti-viral designs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576954      PMCID: PMC20449          DOI: 10.1073/pnas.95.10.5740

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  69 in total

1.  Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.

Authors:  W R Lee; W J Syu; B Du; M Matsuda; S Tan; A Wolf; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

Review 2.  CD4-gp120 interactions.

Authors:  J S McDougal; D R Klatzmann; P J Maddon
Journal:  Curr Opin Immunol       Date:  1991-08       Impact factor: 7.486

3.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.

Authors:  J Rucker; A L Edinger; M Sharron; M Samson; B Lee; J F Berson; Y Yi; B Margulies; R G Collman; B J Doranz; M Parmentier; R W Doms
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.

Authors:  J D Laman; M M Schellekens; Y H Abacioglu; G K Lewis; M Tersmette; R A Fouchier; J P Langedijk; E Claassen; W J Boersma
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

7.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

8.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

9.  Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding.

Authors:  C A Hébert; R V Vitangcol; J B Baker
Journal:  J Biol Chem       Date:  1991-10-05       Impact factor: 5.157

10.  Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region.

Authors:  S R Pollard; M D Rosa; J J Rosa; D C Wiley
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  21 in total

1.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Conserved determinants of enhanced CCR5 binding in the human immunodeficiency virus subtype D envelope third variable loop.

Authors:  Samaporn Teeravechyan; M Essex; Tun-Hou Lee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

3.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

4.  CCR5 interactions with the variable 3 loop of gp120.

Authors:  Kelby B Napier; Zi-xuan Wang; Stephen C Peiper; John O Trent
Journal:  J Mol Model       Date:  2006-05-24       Impact factor: 1.810

5.  Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.

Authors:  Michael D Bobardt; Udayan Chatterji; Lana Schaffer; Lot de Witte; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

6.  Probing sequence variation in the receptor-targeting domain of feline leukemia virus envelope proteins with peptide display libraries.

Authors:  Keith Bupp; Anindita Sarangi; Monica J Roth
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals.

Authors:  Woan-Eng Chan; Hui-Hua Lin; Steve S-L Chen
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization.

Authors:  Alessia Bachis; Eugene O Major; Italo Mocchetti
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

9.  Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications.

Authors:  W K Wang; T Dudek; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

10.  Tyrosine sulfation is prevalent in human chemokine receptors important in lung disease.

Authors:  Justin Liu; Samuel Louie; Willy Hsu; Kristine M Yu; Hugh B Nicholas; Grace L Rosenquist
Journal:  Am J Respir Cell Mol Biol       Date:  2008-01-24       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.